eClinical Technology and Industy News

Genetics May Play Role in Determining Immunity to COVID-19

Excerpt from the Press Release:

Neutralizing antibodies develop within two weeks of a SARS-CoV-2 infection, but their durability and intensity can vary by individual, prompting concerns about the prospects of long-lasting immunity and efficacy of COVID-19 vaccines.

In a PLOS ONE paper, published online February 11, 2021, researchers at University of California San Diego School of Medicine report that individual immune response to SARS-CoV-2, the virus that causes COVID-19, may be limited by the major histocompatibility complex or MHC, a set of variable genes that code for cell surface proteins essential for the adaptive immune system.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?